Form 4: Sarepta Therapeutics Director Stephen Mayo Sells Shares to Cover Tax Obligations

Director Stephen Mayo sold 3,135 shares of Sarepta Therapeutics common stock on March 5, 2024, to cover tax obligations arising from the vesting of restricted stock units.

Summary

• On March 5, 2024, Stephen Mayo, a director of Sarepta Therapeutics, sold 3,135 shares of the company's common stock.
• The sale was executed at a price of $122.96 per share.
• The purpose of the sale was to generate cash for the payment of taxes due as a result of the vesting of certain restricted stock unit awards.
• Following the transaction, Mayo directly owns 6,621 shares of Sarepta Therapeutics.

Sentiment

Score: 6

Explanation: The document describes a routine transaction (stock sale for tax purposes) by a company director. It doesn't contain any information that would significantly impact investor sentiment positively or negatively.

Industry Context

This is a routine transaction for corporate insiders to cover tax obligations related to stock-based compensation. It doesn't necessarily reflect a change in the director's long-term outlook for the company.

Stakeholder Impact

• The sale of shares by a director could have a minor, temporary impact on the stock price, but is unlikely to have a significant long-term effect on shareholders.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates